Who is sponsoring NCT04297488?

NCT04297488 is sponsored by Peking Union Medical College Hospital.

What drugs are being tested in NCT04297488?

Interventions in NCT04297488: Bifidobacteria and Lactobacilli triple viable capsules.

What condition does NCT04297488 study?

NCT04297488 studies HIV-infection/Aids.

Is NCT04297488 still recruiting?

NCT04297488 is currently status unknown. Last updated 9 February 2023.

Last reviewed 2023-02-09 · How we verify

NCT04297488

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Probiotic Supplementation for Those Immune Non-responders With HIV-1 Infection

Status unknown NA Last updated 9 February 2023

What this trial tests

NA trial testing Bifidobacteria and Lactobacilli triple viable capsules in HIV-infection/Aids in 20 participants. Status unknown.

Timeline

1 May 2020

Primary endpoint
1 June 2025

1 July 2025

Quick facts

Lead sponsor	Peking Union Medical College Hospital
Phase	NA
Status	Status unknown
Study type	INTERVENTIONAL
Allocation	na
Design	single group
Masking	none
Primary purpose	supportive care
Enrollment	20
Start date	1 May 2020
Primary completion	1 June 2025
Estimated completion	1 July 2025
Sites	1 location across China

Drugs / interventions tested

Bifidobacteria and Lactobacilli triple viable capsules

Conditions studied

HIV-infection/Aids — all drugs for HIV-infection/Aids →

Sponsor

Peking Union Medical College Hospital

Who can join

Adults 18 to 65, any sex, with HIV-infection/Aids. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Gut bacterial community diversity and composition, immune recovery and activation in peripheral plasma/mucosa, plasma levels of gut damage, microbial translocation and inflammation at baseline and after 6 months of receiving intervention will be analyzed.

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

Lights and Shadows of Microbiota Modulation and Cardiovascular Risk in HIV Patients.
Villoslada-Blanco P, Pérez-Matute P, Oteo JA. · · 2021 · cited 4× · PMID 34202210 · DOI 10.3390/ijerph18136837

Verify or expand the search:

Other Peking Union Medical College Hospital trials

Trials by the same sponsor.

NCT07466251 — PCSK9 Inhibitor for Intracranial Atherosclerosis Related Acute Ischemic Stroke · Phase 4 · not yet recruiting
NCT06743321 — Speech-to-speech Voice-cloning Care (SVCC) to Improve ICU-acquired Anxiety for Critically Ill Patients · NA · not yet recruiting
NCT07590336 — 68Ga-NYM207 PET/CT Imaging in Hepatocellular Carcinoma · Phase 1, PHASE2 · not yet recruiting
NCT07515976 — Mapping of Genomic Structural Variations in Major Birth Defects · not yet recruiting
NCT07386756 — Early Precise Identification and Intervention Strategies for Individuals at High Risk of Prediabetes · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT04297488 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Peking Union Medical College Hospital
Last refreshed: 9 February 2023

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04297488.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing